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The highly metastatic human melanoma cell line BLM was transfected with the ElA  or EIA+E1B
regions of adenovirus 5 (Ad5). A series of progression markers, correlated with the malignant phenotype
of parental BLM (including calcyclin, thymosin 0 10, plasminogen activator inhibitors types 1 and 2
urokinase type and tissue type plasminogen activators, vimentin, tissue type transglutaminase, and interleu­
kin-6), was collectively repressed in the transfeetants, whereas several control genes were not affected or 
even induced. The apparently coordinate repression of a set of markers by the same regulator gene, Ad5 
ElA in this case, suggests the existence of one pathway under the control of a main switch and predicts 
that one or more as yet unidentified cellular master genes normally exert this function. A reduced oncogenic­
ity was observed after subcutaneous inoculation of the ElA  transfeetants into nude mice and provides
additional evidence in support of a tumor suppressor function of Ad5 E lA . © 1996 Academic Press, inc.
Melanocytic tumor progression is thought to evolve through several distinct stages, from
normal melanocytes to highly invasive melanoma cells capable of metastasis (1,2). A vast 
collection of molecular markers associated with subsequent stages of melanocytic tumors and
expressed in a number of melanoma derived cell lines (for review, see ref. 3) has been 
described.
In the past years we have characterized several reverse progression markers, present in non­
metastatic human melanoma cell lines, as well as positive progression markers, characteristic 
for highly metastatic melanoma cell lines (4-10). While changes in gene regulation drive tumor 
progression, it should be feasible to identify one or a few regulatory genes (e.g. encoding 
transcription factors or coactivators) that control expression of a set of either reverse or positive 
progression markers by characterizing the regulatory elements of available marker genes. 
Alternatively, it may be possible to test a regulatory gene as a candidate to control the 
expression of a set of related marker genes. The experiments described in this report follow 
the latter approach, using the human Ad5 ElA gene as a candidate suppressor gene.
While the human Ad5 ElA  gene is best known for its transforming properties and related 
broad influences on gene regulation (for review, see ref. 11), the introduction of Ad5 ElA into
highly malignant rodent or human cells induced a reduction of the metastatic potential (re­
viewed in ref. 12). The reduced metastatic activity in ElA  transfected cells correlated with
reduced levels e. /  ■* and collagenase type I and type
I Correspondence. Fax: +31-24 3540525. E-mail: g.swart@bioch.kun.nl.
Abbreviations used are: Ad5, adenovirus type 5; IL-6, interleukin-6; PAI-1, plasminogen activator inhibitor type 
1; PAI-2, plasminogen activator inhibitor type 2; SDS-PAGE, polyacrylamide gel electrophoresis in the presence of 
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IV (14), or down-regulation of the proto-oncogene neu (15,16) 
of the normal human c-erbB-2/neu proto-oncogene is a 











were incubated with the M73 anti-El A monoclonal antibody (24). Slides
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patts, Glostrup, Denmark). For actin staining, cells were 
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further characterization, RNA was 
metastatic cell lines MV3 and BLM, and 
BLM.E1-1, BLM.E1-2 and BLM.E1A (after transfection of El A, 
were grown in sufficient amounts to allow RNA isolation
cell lines, BLM.mock, BLM.neo
o f
cells). As expected, El A mRNA expression was only detectable in the three positive transfee
tants, BLM.E1-1
visible (Fig. 2A). In addition, we examined the expression of a panel of positive progression 
marker genes, including calcyclin (4), thymosin /31Q (5), TGase2 (28), PAI-1 (30), PAI-2 (31),
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FIG. 2. Northern blot analysis of human melanoma cell lines, and El A or E1A+E1B transfectants. Ten yug of total 
RNA was loaded in each lane. Lane 1, 1F6; lane 2, MV3; lane 3, BLM; lane 4, BLM.mock; lane 5, BLM.neo; lane 
6, BLMJE1-1; lane 7; BLM.E1-2; lane 8, BLM.E1A. (A) Expression of E1A, PAM , PAI-2, uPA, tPA, TGa-se2. (B) 
Expression of memA, memB, thymosin /?10, calcyclin and c-myc. (C) Expression of p53, nma, nmb and ME49\. (D) 
Expression of hsp70, ft actin and vimentin. Lambda Hindlll was used as a molecular marker; a 18S ribosomal probe 
was used for control hybridization.
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Cell lines were cultured for 48
was de-
. IL-6 values are given as 
pg active protein per ml per 106 cells.
uPA tPA (two novel genes, associated with highly metastatic 
M. van Groningen, unpublished results), vimentin and c-myc (29) 
(note that c-myc showed no differential mRNA expression in our panel of human melanoma
The expression profile of BLM.E1-1, BLM.E1-2 and BLM.E1A showed a specific 
switch off for most of these genes, while thymosin £10 and vimentin were downregulated to
non-metastatic cell line 1F6. The expression of some other genes was hardly
actin, p53, nma and nmb (two novel genes, not expressed in our
and the reverse progression marker ME491 (33). In accor
was greatly increased in El A expressing cells 
the expression of positive progression marker genes is





The secretion of IL-6 into the growth medium by the reference cell lines 
transfectants was assayed by hybridoma growth stimulation (Table 1). The non-
not produce IL-6, whereas the highly metastatic cell
amounts of IL-6 into the growth medium. IL-6 
md BLM.E l-2 was down-regulated to the level of the non-metastatic
to parental BLM, BLM.neo and BLM.mock. IL-6 
was at the level of the parental BLM cell line.
two neo transfectants BLM.neo7
5 3 0
BLM.ElArev, and the El A expressing BLM.E1 and
9
formed large tumors within 6 weeks.
-1 and BLM.E1-
observations indicate that tumor growth of the
DISCUSSION
The presented set of experiments was designed to study molecular mechanisms controlling





























FIG. 3. Growth curves of the tumors from parental BLM, BLM.neo 7, BLM.neo 12, BLM.ElArcv, BLM.E1-1 and 
BLM.E1-2 cell lines in nude mice. Approximately 3 X 106 cells were inoculated s.c. into nude mice. Tumor volumes 
were measured weekly and mice were allowed to sit for three months unless the tumor size interfered with the animal’ 
health. Values are given as a mean of all animals (5 animals per cell line) tested.
the highly metastatic human melanoma cell line BLM by stable transfection, we have observed 
the apparently collective and coordinate suppression of a panel of genes whose expression is 
normally positively related with the malignant BLM phenotype. While some of these positive 
progression markers have a proven functional relation with metastasis, the functions of some 
others, including two novel genes, are unknown in regard to neoplastic progression. The 
apparently coordinate type of intervention is remarkable and novel, and provides evidence for 
the existence of a common pathway of neoplastic progression in melanoma cells.
Significant differences existed in the levels of ElA expression in the three transfectants, 
BLM.E1-1 displaying the highest levels of both mRNA and protein. Despite these variations 
all three El A expressing transfectants were equally capable of suppressing positive progression 
marker gene expression and changing cell morphology. As additional confirmation for the 
presence of ElA activity we observed the well described stimulation of hsplO expression (35) 
in all three transfectants, BLM.EM, BLM.E1-2 and BLM.E1A. The complete suppression of 
several genes (e.g. u-PA, PAI-1) in all transfected cell clones is a strong argument in favor 
of homogeneity of the cultures analyzed. The presence of the ElA  gene had no effect on p53 
transcript levels, but it is known that ElA  stabilizes the p53 tumor suppressor protein and 
promotes apoptosis (36). Continuous culturing may, therefore, select for cells that have lost 
ElA  expression. Accompanying the loss of ElA expression, BLM.ElArev had reverted to the 
parental phenotype, further confirming that ElA activity is responsible for the observed pheno­
typic changes. The Ad5 E1B gene products inhibit ElA associated apoptosis (37). Therefore,
transfectants and, indeed, ElA expression is apparently stable in BLM.E1-1 and BLM.E1-2 
cell lines.
In addition to the differences in the gene expression profiles, the ElA transfectants display 
changes in cell morphology and cytoskeletal organization. This phenomenon is not normally 
related with melanoma progression (compare ref. 38). Apparently, ElA proteins do not only 
cause suppression of late progression marker genes but have broader effects. This is not 
surprising in view of the number and nature of the cellular factors that are known to associate
814
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with El A (11,39). El A induced phenotypic alterations were more often associated with a 
cytoskeletal reorganization, the resultant patterns being cell-type-dependent (38,40).
Our data provide new evidence in support of a tumor suppressor function for ElA , as 
suggested recently by several other groups (12,40-43). Reduced oncogenicity would be a likely 
and logical consequence of the observed suppression of positive progression marker genes. 
Subcutaneous inoculation of the transfected melanoma cells into nude mice indeed showed 
that the presence of ElA  significantly reduced tumor growth. The properties of the reverted 
cell line BLM.E1 Arev corresponded also in this test with those of parental BLM.
to this subject no unifying concept has emerged yet. The ample data are listed in recent reviews 
(11,39). In general, it is concluded that the mechanism does not seem to be mediated by one 
specific factor or interaction. Furthermore, it is pointed out that the qualitative effect (suppres-
sion or promotion) is
factors (RB, p i07, pl30, p300). It is known that ElA inhibits cAMP-dependent activation of 
the IL-6 promoter due to interac tions with and inhibition of CBP (44). The mechanisms of 
the effects described in this report have to be elucidated in further studies.
In summary, our results add new evidence to the earlier observed suppression/reversion of 
neoplastic progression by ElA  (15,17,40,42,43,45). More importantly, while the apparent 
inhibition of the oncogenic potential of several human tumor cell lines was ascribed to the 
mere suppression of individual genes essential for advanced progression, our data show that 
ElA  interference is more comprehensive and concerns the specific suppression of all tested
genes whose expression is positively correlated with neoplastic progression panel of
human melanoma cell lines of increasing metastatic potential. We therefore conclude that EIA 
fulfills the role of a “master gene” , i.e. a gene responsible for the transition of one phenotype 
to another. The coordinate intervention realized by a viral gene suggests that neoplastic progres­
sion proceeds along a common pathway(s), which may be equally well controlled by (an) as 
yet unidentified cellular factor(s).
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